Literature DB >> 22706225

Prevalence of human papillomavirus genotypes in cervical cancer.

Teeraporn Chinchai1, Jira Chansaenroj, Sukumarn Swangvaree, Pairoj Junyangdikul, Yong Poovorawan.   

Abstract

BACKGROUND AND
OBJECTIVE: Cervical cancer is the second most common female genital cancer worldwide. There is strong epidemiological and molecular evidence indicating that human papillomavirus (HPV) infection is a necessary event in the development of cervical intraepithelial lesion and subsequent invasive carcinoma. The aim of this study was to investigate the HPV genotype distribution and prevalence in cervical cancer of Thai women.
MATERIALS AND METHODS: One hundred fifty-five cervical cancer specimens were enrolled in this study. The HPV genotypes were determined by means of the combined use of a line probe assay (INNO-LiPA) and DNA chip methods.
RESULTS: Of the overall prevalence of HPV in the study group, 83.2% and 11.6% of the cases had single and multiple genotype infections, respectively. The most prevalent genotypes were HPV 16 (51%), followed by HPV 18 (20%), HPV 52 (10.3%), HPV 58 (5.8%), and HPV 33 (4.5%). All HPV genotypes found in this study could be classified as 13 high-risk HPV, 2 low-risk HPV, and 2 additional types. Of the specimens, 94.8% had at least one high-risk HPV genotype infection.
CONCLUSION: As for the potential benefits of commercially available prophylactic vaccines to prevent HPV infection in Thailand, both vaccines (bivalent and quadrivalent) can protect from HPV-related cervical cancer in only approximately 71%. Therefore, screening programs such as routine Papanicolaou test, cytology, and HPV DNA detection are still essential for cervical cancer prevention. Moreover, future generations of HPV vaccines should also include the other most common genotypes and decrease the severe adverse effects reported at the present time.

Entities:  

Mesh:

Year:  2012        PMID: 22706225     DOI: 10.1097/IGC.0b013e318259d904

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  12 in total

1.  Molecular genotyping of human papillomavirus l1 gene in low-risk and high-risk populations in Bangkok.

Authors:  Pornsawan Leaungwutiwong; Busara Bamrungsak; Akanitt Jittmittraphap; Pannamas Maneekan; Nathamon Kosoltanapiwat; Thareerat Kalambaheti; James F Kelley
Journal:  Sex Transm Dis       Date:  2015-04       Impact factor: 2.830

2.  Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs.

Authors:  Nuttavut Kantathavorn; Chulabhorn Mahidol; Narongrit Sritana; Thaniya Sricharunrat; Natacha Phoolcharoen; Chirayu Auewarakul; Narongchai Teerayathanakul; Chantanee Taepisitpong; Siriporn Saeloo; Gaidganok Sornsamdang; Wandee Udomchaiprasertkul; Waraphorn Krongthong; Arpaporn Arnamwong
Journal:  Infect Agent Cancer       Date:  2015-03-02       Impact factor: 2.965

Review 3.  Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?

Authors:  Lj van Bogaert
Journal:  Ann Med Health Sci Res       Date:  2013-07

4.  Expected efficacy of HPV vaccine in prevention of cervix cancer in Thailand.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  South Asian J Cancer       Date:  2014-07

5.  Specific genotypes of human papillomavirus in 125 high-grade squamous lesions and invasive cervical cancer cases from Congolese women.

Authors:  Luc Magloire Anicet Boumba; Lahoucine Hilali; Mustapha Mouallif; Donatien Moukassa; Moulay Mustapha Ennaji
Journal:  BMC Public Health       Date:  2014-12-23       Impact factor: 3.295

6.  Prevalence and incidence of external genital warts in a sample of Italian general female population.

Authors:  Barbara Suligoi; Giorgio Vittori; Maria Cristina Salfa; Laura Timelli; Dario Corsini; Giovanni Fattorini; Luciano Mariani
Journal:  BMC Infect Dis       Date:  2017-02-06       Impact factor: 3.090

7.  Prevalence of human papillomavirus in the cervical epithelium of Mexican women: meta-analysis.

Authors:  Raúl Peralta-Rodríguez; Pablo Romero-Morelos; Vanessa Villegas-Ruíz; Mónica Mendoza-Rodríguez; Keiko Taniguchi-Ponciano; Beatriz González-Yebra; Daniel Marrero-Rodríguez; Mauricio Salcedo
Journal:  Infect Agent Cancer       Date:  2012-12-03       Impact factor: 2.965

8.  Risk factors and distribution of oncogenic strains of human papilloma virus in women presenting for cervical cancer screening in Port Harcourt, Nigeria.

Authors:  Nyengidiki Tamunomie Kennedy; Durugbo Ikechukwu; Bassey Goddy
Journal:  Pan Afr Med J       Date:  2016-03-11

Review 9.  Current Technologies and Recent Developments for Screening of HPV-Associated Cervical and Oropharyngeal Cancers.

Authors:  Sunny S Shah; Satyajyoti Senapati; Flora Klacsmann; Daniel L Miller; Jeff J Johnson; Hsueh-Chia Chang; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2016-09-09       Impact factor: 6.639

10.  Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.

Authors:  Surapan Khunamornpong; Jongkolnee Settakorn; Kornkanok Sukpan; Prapaporn Suprasert; Jatupol Srisomboon; Suthida Intaraphet; Sumalee Siriaunkgul
Journal:  PLoS One       Date:  2016-06-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.